Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FHCY5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $31,454
Award facts
- Contract value 100% obligated
- $31,453.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $31,453.92 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml autoinjector vials. This firm fixed-price delivery order, issued on December 9, 2025, with an ultimate completion date of December 31, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The order will be fulfilled at the contractor's Park Ridge facility.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide diverse pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's PPV-G GEN V contract, valued at $499.999 billion with a completion date of December 31, 2036, establishes the company as a critical regional pharmaceutical supplier supporting military healthcare operations. The contractor's established performance across numerous delivery orders spanning oncology treatments, biologics, vaccines, and specialty pharmaceuticals demonstrates its capability to fulfill the specialized medical supply requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FHCY5?
SPE2DR26FHCY5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 9, 2025.
How much is contract SPE2DR26FHCY5 worth?
The government has obligated $31,454 on SPE2DR26FHCY5.
Is contract SPE2DR26FHCY5 an order under another contract?
Yes. SPE2DR26FHCY5 is a delivery order under SPE2DR25D9207, an indefinite delivery contract.
Was contract SPE2DR26FHCY5 competed?
The extent of competition for SPE2DR26FHCY5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award